KOSPIBiotech & Pharma016580

Whanin Pharm

₩10,560▼ 1.03%2026-11-18 close
Market Cap
₩196.4B
Turnover
₩200M
Volume
20K
Shares out.
18.6M
PER
8.3×
PBR
0.5×
EPS
₩1,285
Dividend Yield
2.80%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩300 per share · Prices as of the 2026-11-18 close

01

Report overview

Psychiatry-focused drugmaker: whether the profit recovery holds

Whanin Pharm is a CNS-focused drugmaker whose profits fell in 2025 and recovered in early 2026, but operating profit has declined for two straight quarters since the first quarter of 2026, so whether the recovery holds is the next thing to watch.

  1. 1

    Revenue edged down to KRW 255.2 billion in 2025, but has increased for three consecutive quarters from the first quarter of 2026 through the third quarter.

  2. 2

    Operating profit peaked at KRW 30.2 billion in 2023, then fell in 2024 and 2025, and the operating margin dropped from 15.0% in 2022 to 5.1% in 2025.

  3. 3

    Quarterly operating profit peaked at KRW 9.38 billion in the first quarter of 2026, then declined for two consecutive quarters to KRW 7.89 billion and KRW 7.53 billion, although the third-quarter figure was up 111.8% year on year.

  4. 4

    Rising cost of sales and higher fixed costs from the Hyangnam plant are cited as the main drivers of margin compression in 2024 and 2025.

  5. 5

    Psychoneurological agents account for more than 80% of sales, and a large share of production falls under the first-round drug price re-evaluation, which is a structural variable.

02

Business structure

Whanin Pharm manufactures and supplies finished pharmaceuticals to hospitals and other institutions, and its business centers on central nervous system (CNS) drugs. Psychoneurological agents generate more than 80% of sales, which makes its product concentration high.

According to the company's business overview table, psychoneurological agent sales rose from KRW 155.3 billion in 2022 to KRW 210.8 billion in 2025, while circulatory system drugs and osteoporosis treatments declined over the same period. Quetiapine and Eplam are named as flagship brands in this category.

Production runs through two plants, Anseong and Hyangnam, and after the Hyangnam addition, psychoneurological agent capacity grew from about KRW 67 billion in 2022 to about KRW 100.4 billion in 2024. The company is also expanding in licensed products.

In 2023 it signed a distribution deal with GSK covering six products, including antidepressant, Parkinson's and migraine treatments, and in 2024 it secured exclusive domestic sales rights to Arava, a rheumatoid arthritis drug, with Sanofi-Aventis Korea.

Its subsidiaries are AmbroBio&P, which handles drug R&D, and AsU, which handles general distribution. Because psychiatric treatment revenue tracks patient visits, growth in psychiatric diagnosis and prescriptions feeds directly into sales.

In competition, the company holds the number one position in Korea's psychiatric therapy drug market by IMS data for 2025. Based on its own calculation, it ranked eighth by 2023 revenue, at about 12.3% of the revenue of market leader Yuhan.

For 2026 it has highlighted global partnerships centered on China and Taiwan, along with diversification into animal health and health functional foods.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩65.7B₩3.6B5.4%
2025Q4₩65.1B₩1.5B2.3%
2026Q1₩71.2B₩9.4B13.2%
2026Q2₩71.4B₩7.9B11.1%
2026Q3₩71.6B₩7.5B10.5%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩198.9B₩29.8B₩23.9B15.0%7.2%10.6%
2023₩230.4B₩30.2B₩29.8B13.1%8.3%12.0%
2024₩259.6B₩21.5B₩23.4B8.3%6.2%13.0%
2025₩255.2B₩13B₩13.6B5.1%3.2%13.7%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-12

04

Earnings analysis

Annual revenue rose from KRW 198.9 billion in 2022 to KRW 230.4 billion in 2023 (up 15.8% year on year) and KRW 259.6 billion in 2024 (up 12.7%), then edged down to KRW 255.2 billion in 2025 (down 1.7%). The largest year in the 2022–2025 period was 2024.

Operating profit reached a peak of KRW 30.2 billion in 2023 (up 1.2%) and then fell 28.8% to KRW 21.5 billion in 2024 and 39.4% to KRW 13 billion in 2025, a two-year decline.

Net profit attributable to controlling shareholders peaked at KRW 29.8 billion in 2023, then fell 21.5% to KRW 23.4 billion in 2024 and 41.9% to KRW 13.6 billion in 2025. Net profit including non-controlling interests was KRW 13.6 billion in 2025.

The operating margin fell from 15.0% in 2022 to 13.1% in 2023, 8.3% in 2024 and 5.1% in 2025. Cost pressure from the capacity expansion explains much of the decline, as cost of sales rose from 50.34% of revenue in 2022 to 63.88% in 2024 according to a third-party tally.

In its business report, the company attributed the margin decline to higher merchandise cost from the GSK products, higher inventory valuation allowances on export items and higher production costs from equipment investment.

In 2025, labor costs rose from KRW 52.5 billion to KRW 59 billion, and depreciation from KRW 8.5 billion to KRW 9.8 billion.

Quarterly operating profit bottomed at KRW 1.48 billion in the fourth quarter of 2025 on revenue of KRW 65.1 billion, then peaked at KRW 9.38 billion in the first quarter of 2026 on revenue of KRW 71.2 billion.

Operating profit then declined to KRW 7.89 billion in the second quarter and KRW 7.53 billion in the third quarter, while third-quarter revenue reached KRW 71.6 billion.

Cumulative operating profit for the first nine months of 2026 was KRW 24.8 billion, according to a press report on the preliminary disclosure released on October 29, 2026. Operating cash flow was KRW 16.9 billion in 2022, KRW 23.2 billion in 2023, KRW 20.7 billion in 2024 and KRW 9.04 billion in 2025.

05

Industry analysis

The psychiatric drug market is growing. Analysts point to rising psychiatric diagnoses and prescriptions and to the expansion of mental health care institutions, which together are increasing patient visits. By IMS data, the company was ranked the top domestic firm in psychiatric therapy drugs for 2025.

Pricing is a source of uncertainty, however. Based on Ministry of Food and Drug Safety production records, products linked to the first-round drug price re-evaluation account for 61.2% of total finished-drug production value.

The timing of the final price adjustment could be staggered over three years depending on the outcome of new certification, which makes timing hard to predict. In the product mix, circulatory, peptic ulcer and osteoporosis lines are gradually shrinking as a share of sales, while psychoneurological agents are rising.

Compared with diversified drugmakers, the company is a specialist CNS company, and by its own 2023 revenue calculation it ranks eighth, at about 12.3% of the revenue of market leader Yuhan, so the scale gap remains wide.

Even if the sector backdrop is favorable, earnings depend on plant utilization and cost structure, and the company's own fixed-cost absorption matters more to its margin than the industry supply cycle.

06

Outlook

In a corporate value enhancement plan disclosed in March 2026, the company set out consolidating its position in the psychiatric therapy drug market and a 2026 revenue target of KRW 280 billion.

Cumulative revenue for the first three quarters of 2026 is about KRW 214.2 billion, so whether the full-year target is met will be confirmed with the annual results in early 2027.

The same plan includes strengthening global partnerships centered on China and Taiwan and diversifying into animal health products and health functional foods.

A sell-side estimate also exists: in a March 2026 report, LS Securities projected 2026 revenue of KRW 270.6 billion and operating profit of KRW 17.2 billion, and put 2027 and 2028 operating profit at KRW 19.9 billion and KRW 22.8 billion.

Against that estimate, cumulative operating profit for the first three quarters of 2026 of KRW 24.8 billion already exceeds the full-year forecast. The same report expected margins to recover gradually from 2026 rather than returning quickly to levels above 10%.

The recovery drivers cited were the expansion of higher-margin psychoneurological channels, a base effect from the higher fixed costs in 2025, and rising utilization at the new Hyangnam plant. On the product side, news reports covered the introduction of an ADHD treatment from Taiwan's ANXO.

The next items to check are whether the quarterly operating margin regains the first-quarter 2026 level and how Hyangnam plant utilization feeds into the cost of sales.

07

Valuation

PER
8.3×
PBR
0.5×
ROE
5.7%
EPS
₩1,285
BPS
₩23,577
Dividend per share
₩300

Valuation has to be read against the pace of the profit recovery and how much of it the share price already reflects. Price-to-book sits at a discount to the company's own historical range. Debt relative to equity is low, which points to a stable balance sheet.

Net cash was reported at KRW 63.1 billion as of March 2026. The company has kept paying dividends since 2017, and the 2025 payout ratio was presented as 40.8%. Profits fell from 2024 through 2025 and turned toward recovery in 2026.

If the recovery holds, the same share price would correspond to a lower multiple of earnings. Conversely, because quarterly profit declined in the second and third quarters of 2026, the multiple interpretation depends on whether the recovery is temporary or structural.

The sell-side estimates cited here date from March 2026 and should be read in that context. The more useful approach is to examine how business metrics relate to the share price, rather than the absolute level of the multiple.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-12

08

Bull factors

Expanding psychiatric demand and prescription base

Rising psychiatric diagnoses and prescriptions and the expansion of mental health institutions are lifting patient visits, a supportive backdrop for sales. One tally shows that revenue and operating profit in the first half of 2026 both grew sharply from a year earlier. Because psychoneurological agents exceed 80% of sales, the company passes this demand flow through directly.

Entry into a profit recovery phase

According to a press report on the preliminary October 29, 2026 disclosure, cumulative operating profit for the first three quarters of 2026 was KRW 24.8 billion, well above the same period of 2025. Third-quarter operating profit was up 111.8% year on year.

Revenue has risen for three consecutive quarters since the fourth-quarter 2025 low, another sign of recovery on the top line.

Financial stability and room for shareholder returns

Net cash was reported at KRW 63.1 billion as of March 2026, and the debt-to-equity ratio was 13.7% in 2025, a low level. Dividends have been maintained since 2017, with the 2025 payout ratio presented as 40.8%. A large cash position widens room for investment and shareholder returns.

09

Bear factors

Rising cost ratio and fixed-cost burden

Cost of sales rose from 50.34% of revenue in 2022 to 63.88% in 2024, pulling down the operating margin. Higher labor and depreciation costs in 2025 point in the same direction. The operating margin fell from 15.0% in 2022 to 5.1% in 2025, and operating cash flow declined to KRW 9.04 billion in 2025.

Slowdown after the quarterly profit peak

The first quarter of 2026 was the operating profit peak, and operating profit then declined in the second and third quarters. Third-quarter operating profit of KRW 7.53 billion was down 4.6% from the prior quarter. The year-on-year gain is large, but the sequential trend has slowed.

Concentration in psychoneurological agents and limits to expansion

Psychoneurological agents account for more than 80% of sales, so the portfolio is concentrated in one category. One analysis notes that the CNS share of sales has barely changed since 2011. By its own calculation, the company ranked eighth by 2023 revenue, leaving a wide gap to large diversified drugmakers.

10

Risk factors

Drug pricing policy risk

By Ministry of Food and Drug Safety production records, products linked to the first-round drug price re-evaluation make up 61.2% of total finished-drug production value. The final adjustment timing could be spread over three years depending on the new certification results. Because the portfolio is centered on psychoneurological agents, any price cut would flow directly into margins.

Dependence on licensed products and cost structure

The company explains that higher merchandise cost came from rising sales of licensed products such as those from GSK and Sanofi. As the share of licensed products grows, profitability can fall below that of in-house products.

Analysts attribute the 2025 margin decline to the combination of higher cost ratios and a larger share of lower-margin products.

Pace of recovery and fixed-cost absorption

One sell-side analyst expected margins to recover gradually rather than quickly return above 10%. Fixed costs can be absorbed only once Hyangnam plant utilization rises enough. With profit down in the second and third quarters of 2026, uncertainty about the pace of recovery remains.

11

What to watch next

  1. Around January–February 2027

    Preliminary fourth-quarter and full-year 2026 results. The key questions are whether annual revenue reaches the KRW 280 billion target and whether the fourth-quarter operating margin regains the first-quarter 2026 level. Cumulative revenue for the first three quarters of 2026 was about KRW 214.2 billion.

  2. Around late March 2027

    Filing of the 2026 annual business report. It will serve as the reference for how cost of sales, merchandise cost, labor and depreciation changed from 2025.

  3. After late 2026, depending on announcement timing

    The final outcome of the first-round drug price re-evaluation. Because the portfolio is concentrated in psychoneurological agents, the size and timing of any adjustment will shape the margin path.

  4. Mid-May 2027

    The first-quarter 2027 report. It is the next quarterly checkpoint for whether higher Hyangnam plant utilization and expansion of psychiatric channels translate into a sustained margin recovery.

12

Overall view

Whanin Pharm is a CNS specialist whose psychoneurological agents account for more than 80% of sales. Operating profit and margin have declined since peaking in 2023, mainly because of cost pressure and fixed costs tied to the Hyangnam plant.

In 2026, quarterly operating profit peaked in the first quarter, and cumulative operating profit for the first three quarters reached about KRW 24.8 billion, up sharply from the same period of 2025.

However, operating profit declined in the second and third quarters, and the external variable of drug price re-evaluation remains. Financially, net cash and a low debt ratio support stability.

Demand growth in psychiatric care and the profit recovery are the strengths, while the cost structure and product concentration are the weaknesses, and both should be weighed equally.

The next items to check are preliminary fourth-quarter and full-year 2026 results and the cost ratio and operating margin in the 2026 annual business report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. jobkorea.co.kr
  2. ibtomato.com
  3. medicopharma.co.kr
  4. whanin.com
  5. biotimes.co.kr
  6. fntoday.co.kr
  7. m.dailypharm.com
  8. comp.wisereport.co.kr
  9. dailyinvest.kr
  10. medipana.com
  11. m.news.nate.com
  12. newsquest.co.kr
  13. digitaltoday.co.kr
  14. medipana.com
  15. press.todayan.com
  16. bosa.co.kr
  17. kpanews.co.kr
  18. kmpnews.co.kr

Report written 2026-11-12 · Data as of 2026-11-11

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis